tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Archive for 'News Features'

GBT Technologies Transforming the Future Healthcare AI Market

GBT Technologies Transforming the Future Healthcare AI Market

Written by Ι Stock Market Media — January 16, 2020

GBT Technologies, Inc. (OTC PINK: GTCH) (GBT) is among a handful of companies that are developing Artificial Intelligence (AI) and Internet of Things (IoT) solutions that are expected to transform the future of the healthcare industry.  Both segments of the industry, AI and IoT, are growing exponentially, and GBT’s technology is ideally positioned to succeed in this burgeoning marketplace.

GBT will grow its footprint in the industry with its “Avant! AI” (Avant!) technology, a ...

Read More →
0

GBT Technologies’ AI Engine Improving Microchip Production and Creating Expert Smart Apps

GBT Technologies’ AI Engine Improving Microchip Production and Creating Expert Smart Apps

Written by Ι Stock Market Media — December 3, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) (GBT) is steadily growing its footprint in the high-tech space while also expanding its already strong portfolio of technologies that continue to increase the company’s position in the industry.  GBT is segmented into 5 different areas of growth, but its work in the artificial intelligence or AI industry continues to be the company’s central focus, and its AI engine, “Avant! AI,” could prove to be an industry-leading ...

Read More →
0

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

Written by Ι Stock Market Media — November 12, 2019

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can submit an Investigational New Drug application (IND) to the U.S. FDA.  PharmaCyte’s IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).  With the FDA’s approval to begin a clinical trial, PharmaCyte’s opportunities for funding improve dramatically.

PharmaCyte has already ...

Read More →
0

GBT Technologies Competing in $4 Trillion AI Market with Disruptive Technology

GBT Technologies Competing in $4 Trillion AI Market with Disruptive Technology

Written by Ι Stock Market Media — November 8, 2019

GBT Technologies, Inc. (OTC PINK: GTCH) has a vast portfolio of intellectual property that spans both the Artificial Intelligence (AI) and Internet of Things (IoT) markets.  But the company’s central focus is on a technology called “Avant! AI”—a technology that could become commonplace in both businesses and households worldwide.  It is the extremely promising potential of Avant! that has GBT Technologies (GBT) ideally positioned to compete in what Gartner, a leading research and ...

Read More →
0

ICC International Cannabis Corp. Competing in Explosive Worldwide Cannabis Market with Unique Global Strategy

ICC International Cannabis Corp. Competing in Explosive Worldwide Cannabis Market with Unique Global Strategy

Written by Ι Stock Market Media — February 22, 2019

Make no mistake about it the growth of the worldwide legal cannabis industry is exploding exponentially. One key driver behind this explosion is the many nations that have been decriminalizing cannabis and legalizing the use of marijuana for both medical and recreational uses. With more new countries dotting the legal cannabis landscape seemingly every day, ICC International Cannabis Corp. or “ICC” (OTC Markets: WLDCF) (CSE: WRLD.U) (FWB: 8K51) is capitalizing on the ...

Read More →
0

PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

Written by Ι Stock Market Media — February 4, 2019

Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...

Read More →
0
Page 1 of 23 12345...»
ContactUs.com